Search Results

On January 14, 2025, the State Administration for Market Regulation (SAMR, 国家市场监督管理总局) published the Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks (the Guidelines, 医药企业防范商业贿赂风险合规指引). The Guidelines are the final version of the Draft Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks (the Draft or the Draft Guidelines) which were published for public comment on October 11, 2024. The finalized Guidelines took effect upon publication. 

On November 28, 2024, China’s National Medical Products Administration (NMPA, 国家药品监督管理局), China’s equivalent of the U.S. Food and Drug Administration, issued the Draft Administrative Measures for Management of Medical Representatives for public comment (the Draft Management Measures, 医药代表管理办法) in conjunction with six other government agencies. The Draft Management Measures were issued for public comment, with a deadline of December 13, 2024.

On October 10, 2024, the National Medical Products Administration (NMPA) released the Draft Rule on Rewarding Internal Whistleblowers for Reporting on the Quality and Safety Issues of Drugs and Medical Devices (the Draft Rule) for public comment, due by November 9, 2024 . The Draft Rule marks a milestone in the development of China’s regulatory system for pharmaceuticals and medical devices and reflects Chinese regulators’ increasing use of best practices from other jurisdictions as well as their continued focus on the healthcare sector. Once effective, the Draft Rule may lead to more enforcement actions by Chinese authorities. Pharmaceutical and medical device companies operating in China should continue to monitor the development of the Draft Rule.

On October 11, 2024, the State Administration for Market Regulation (SAMR, 国家市场监督管理总局) issued the Draft Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks (the Draft Guidelines, 医药企业防范商业贿赂风险合规指引).